Trigere står i kø
Upcoming milestones
1H2019: ONCOS-102 phase I trial in checkpoint inhibitor
refractory advanced melanoma
– ORR and immune data first cohort
1H2019: TG02 phase I trial in colorectal cancer
– Immune activation and mechanistic data (TG
monotherapy cohort)
1H2019: TG01 phase I/II trial in resected pancreatic cancer
– 3-year survival data
Outlook
There is much excitement in the industry for the potential of oncolytic viruses and with our
ONCOS platform we have the potential to become a key player in this market. We keep in
frequent contact with a number of pharmaceutical and biotech companies regarding, inter
alia, collaborations on trials and supply of combination products. We have four ongoing
clinical trials for our ONCOS-102 program, which delivered encouraging data during the
year and we expect several meaningful data read-outs over the next 12-18 months.
We remain confident in the potential of the TG neoantigen vaccine platform to treat mutant
RAS cancers as shown by the encouraging results from the TG01 trial in resected
pancreatic cancer. We are in active discussions with a number of collaborative groups who
have expressed interest in sponsoring pancreatic cancer combination trials. We are also
excited by the potential of TG02, our second-generation pipeline candidate from the TG
platform, which is currently being tested in a phase Ib exploratory trial in colorectal cancer.
We enter 2019 with optimism and look forward to providing further updates on our clinical progress.